Roche, Biogen Suffer Setback With Experimental Drug - Wall Street Journal

[INCIID News Feed]

<img alt="" height="1" width="1" />
Roche, Biogen Suffer Setback With Experimental Drug
Wall Street Journal
ZURICH--Roche Holding AG and Biogen Idec Inc. said Monday they suspended a rheumatoid arthritis program using drug candidate ocrelizumab because of safety concerns, further cutting the experimental drug&#39;s market potential. ...
Roche suspends arthritis treatment after deathsReuters
Infections and deaths force Biogen, Roche to suspend blockbuster programFierceBiotech
Roche, Biogen Idec Suspend Tests for Arthritis DrugBusinessWeek
MarketWatch -The FINANCIAL -Pharma Times
all 22 news articles &raquo;


More...